News

PeriCor Therapeutics has announced positive preclinical results for cardioprotective agent, GP531, at the European Heart Failure Congress 2009 in Nice, France. The study was funded by PeriCor and

PDI, a provider of sales and marketing support to US pharmaceutical companies, and The Medical Affairs Company, provider of customized medical science laison and medical affairs services, have

Peregrine has highlighted the progress it has achieved in its Phase II program, assessing the combination of bavituximab and chemotherapy in three separate cancer trials. Bavituximab is a

Vical has received US Patent No. 7537768, covering the use of influenza virus gene sequences in a universal vaccine that could provide protection against circulating seasonal strains as

Novartis has announced that the investigational biological therapy Ilaris produced rapid and sustained remission of symptoms in patients with a rare and potentially life-threatening auto-inflammatory disease, cryopyrin-associated periodic

Johnson & Johnson has announced the results of ongoing phase 2, randomized, placebo-controlled trial of the investigational drug TMC207. The drug will be used for the treatment of

Net sales attributable to the epilepsy indication of $140 million compared to $115.3 million in fiscal year 2008, a 21% increase; Gross margin of 86.0%, compared with 82.6%

Cegedim Dendrite has announced a 3 year agreement with Sanofi Aventis to provide Mobile Intelligence CRM solution to over 20,000 users across 28 countries including US, France and

The agreement ensures that the hospital is equipped with solutions that put clinicians’ and patients’ needs at the centre of care. Medical equipment will be replaced in line